Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1134907

	registered interest
	date	26/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	100,000 Genomes Project
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to evaluate the 100,000 Genomes Project.
	tabling member constituency	Birmingham, Yardley
	tabling member printed	Jess Phillips
	uin	269788
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>As a Government Major Project, the 100,000 Genomes Project has been under regular review by the Infrastructure and Projects Authority (IPA) which provides independent assurance of the most complex and strategically significant projects across Government. As part of this, the 100,000 Genomes Project has undergone several significant reviews which considered the Project’s delivery, requiring the collation of extensive documentation evidencing the progress of the Project and several days of interviews with key stakeholders. Conclusions of each review were shared across delivery partners to inform successful delivery of the Project.</p><p>The Department, Genomics England and NHS England recognised the importance in embedding robust testing, assessment and evaluation throughout the delivery of the Project to inform the introduction of whole genome sequencing in the National Health Service under the new Genomics Medicine Service.</p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 05/07/2019 11:40:47 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4370 label Biography information for Jess Phillips

1135751

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	100,000 Genomes Project
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether those who have taken part in the NHS 100,000 Genome Project are being denied access to their own genome data; and if so, why.
	tabling member printed	Lord Scriven
	uin	HL16844
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>Genomics England is committed to returning results to every patient in the 100,000 Genomes Project via their National Health Service clinical team. All of the patient results will have been returned to the NHS by the end of the year.</p><p>Under the Data Protection Legislation, participants in the 100,000 Genomes Project can request their genomic and clinical data. However, a whole genome sequence is around 3 billion letters long and written in code so it is very difficult to interpret. Genomics England can provide access to a visual representation on request or provide access to the raw data. A NHS clinical team is the best route to providing a clinical interpretation of the genome results.</p> answering member printed Baroness Blackwood of North Oxford question first answered 10/07/2019 15:26:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4333 label Biography information for Lord Scriven

1134669

	registered interest
	date	25/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Abortion
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether there are any circumstances in which a pregnancy that does not (1) pose a risk to the physical health of a mother, and (2) involve a foetus that has been diagnosed with a disability, can be involuntarily terminated.
	tabling member printed	Lord Alton of Liverpool
	uin	HL16636
	answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>A decision to terminate a pregnancy must comply with the legal requirements of the Abortion Act 1967. In circumstances where a person lacks capacity, the courts have the authority to make serious healthcare and treatment decisions, in the best interests of the person and pursuant to the Mental Capacity Act 2005, and this could include whether a pregnancy should be terminated.</p> answering member printed Baroness Blackwood of North Oxford question first answered 05/07/2019 10:55:39 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	738 label Biography information for Lord Alton of Liverpool

1137796

	registered interest
	date	09/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Abortion
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of women who have had abortions mandated by (a) a medical practitioner and (b) the courts against their wises in each of the last three years.
	tabling member constituency	Chesterfield
	tabling member printed	Toby Perkins
	uin	275177
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>Information on the number of women who have been required to have an abortion against their wishes is not collected centrally.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 15/07/2019 12:37:20 answering member 4065 label Biography information for Dame Jackie Doyle-Price
	tabling member	3952 label Biography information for Mr Toby Perkins

1136781

	registered interest
	date	03/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Academic Health Science Networks
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government by what process, during the current development of policy options for Academic Health Science Centres (AHSC), potential new AHSCs can be considered in areas of England currently unrepresented by existing AHSCs.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL16931
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16932 HL16934 question first answered 17/07/2019 16:29:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1136784

	registered interest
	date	03/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Academic Health Science Networks
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of whether the innovations arising from the current phase of Academic Health Science Centres are being made available to patients throughout the NHS.
	tabling member printed	Lord Willis of Knaresborough
	uin	HL16934
	answer	answer is ministerial correction date of answer 17/07/2019 answer text <p>The Department-designated Academic Health Science Centres (AHSCs) along with the Academic Health Science Networks (AHSNs) and the National Institute for Health Research (NIHR) Applied Research Collaborations (ARCs) are all important components of the country’s health research and innovation ecosystem.</p><p>The six current Department-designated AHSCs were made on the basis of an open competition, which was open to eligible National Health Service and University partnerships across England. The recommendations for designation were made to the Department by an international independent panel.</p><p>The remit of the Accelerated Access Collaborative (AAC) has recently been expanded to become the umbrella body across the United Kingdom health innovation eco-system. The AAC has been asked to consider the role of new AHSCs within the health system and to ensure that they complement the innovation landscape, rather than add further complexity to it.</p><p>It is not possible to provide specific details of the scope and nature of the new designation process at this stage given that the AAC is currently actively considering this. However, it is expected that the future designation process would be open to all NHS and University partnerships across England which meet the published specification to apply, including partnerships in areas of England where there is currently no Departmental-AHSC. As with the previous AHSC designation process, any future process will be run via a full and open competition, assessed by an independent expert panel. Rigorous conflict of interest policies will also be in place throughout the process for all involved to ensure any potential conflicts are dealt with appropriately.</p><p>The existing Departmental-AHSC designation will be extended until the end of March 2020 to enable a new designation process to be undertaken. The Department’s expectation is that AHSCs will play an increasingly important role in the health innovation and research landscape over the coming years.</p><p>As currently, the success of any newly designated AHSCs will require close interplay and cooperation between research infrastructure, including NIHR Biomedical Research Centres (BRCs) and the NIHR ARCs, and with the AHSNs and wider innovation landscape.</p><p>As part of annual monitoring of the existing Department-designated AHSCs, examples of innovations arising from them have been reported to have been made available to patients in the NHS. These include:</p><p>- The King’s Health Partners Heart Failure Service, which brings together clinical, research and educational expertise to deliver world class heart care in south London, helping people with heart failure live longer and with better quality of life;</p><p>- University College London Partners AHSC adoption of a Learning Health System to standardise data entry and allowing the widespread trialling of novel tools to detect atrial fibrillation early;</p><p>- The Manchester AHSC working with partners to align research around core health and social care priorities; and supporting the roll out of a single blood test driven decision-aid for patients presenting with chest pain at local emergency departments; and</p><p>- The roll out of the innovative Sleepio app by the Oxford AHSN to support those suffering from insomnia across Oxfordshire, Berkshire and Buckinghamshire.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16931 HL16932 question first answered 17/07/2019 16:29:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4151 label Biography information for Lord Willis of Knaresborough

1137416

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will list (a) the criteria and (b) the timelines for products to be considered in (i) the current and (ii) future review rounds of the Accelerated Access Collaborative.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	274540
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/07/2019 15:23:36 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1137418

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Accelerated Access Collaborative
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what criteria the Accelerated Access Collaborative uses in relation to decision-making on (a) medicines, (b) diagnostic tools and (c) digital services.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	274542
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Accelerated Access Collaborative (AAC) is interested in supporting the most strategically important products that will have the biggest impact on patient health outcomes and delivery of National Health Service services.</p><p>When selecting products, the AAC will consider the following irrespective of innovation type (i.e. medicines, diagnostic tools, and digital products):</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p>Further information is available at the following link:</p><p><a href="https://www.nice.org.uk/aac" target="_blank">https://www.nice.org.uk/aac</a></p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/07/2019 15:33:03 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4131 label Biography information for Jim Shannon

1135532

	registered interest
	date	28/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Addictions: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he plans to return addiction services to NHS commissioning; and if he will make a statement.
	tabling member constituency	Central Suffolk and North Ipswich
	tabling member printed	Dr Dan Poulter
	uin	270772
	answer	answer is ministerial correction date of answer 08/07/2019 answer text <p>There are no plans to return addiction services to National Health Service commissioning. Local authorities are best placed to make decisions on the provision of addiction services based on the needs of their local population. We are investing over £16 billion in local authority public health services over the five years of the 2015 Spending Review until 2020/21. Public health funding for 2020 onwards, including for addiction services, will be considered carefully in the next Spending Review, in the light of the available evidence.</p><p>No formal assessment has been made of the effectiveness of the commissioning of addiction services by local authorities. However, the Care Quality Commission (CQC) routinely carries out reviews of residential substance misuse services and community substance misuse services. The majority of residential substance misuse centres and community substance misuse centres commissioned by local government have been rated good or outstanding. Public Health England provides local authorities with a range of data, guidance, tools and bespoke support to help them in their ongoing work of commissioning addiction treatment services. There were 121,332 people who exited the drug and alcohol treatment system in 2017 to 2018, with 48% (58,718) having successfully completed their treatment, free from dependence.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 270773 question first answered 08/07/2019 16:08:50 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3932 label Biography information for Dr Dan Poulter

1135533

	registered interest
	date	28/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Addictions: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the commissioning of addiction services by local authorities.
	tabling member constituency	Central Suffolk and North Ipswich
	tabling member printed	Dr Dan Poulter
	uin	270773
	answer	answer is ministerial correction date of answer 08/07/2019 answer text <p>There are no plans to return addiction services to National Health Service commissioning. Local authorities are best placed to make decisions on the provision of addiction services based on the needs of their local population. We are investing over £16 billion in local authority public health services over the five years of the 2015 Spending Review until 2020/21. Public health funding for 2020 onwards, including for addiction services, will be considered carefully in the next Spending Review, in the light of the available evidence.</p><p>No formal assessment has been made of the effectiveness of the commissioning of addiction services by local authorities. However, the Care Quality Commission (CQC) routinely carries out reviews of residential substance misuse services and community substance misuse services. The majority of residential substance misuse centres and community substance misuse centres commissioned by local government have been rated good or outstanding. Public Health England provides local authorities with a range of data, guidance, tools and bespoke support to help them in their ongoing work of commissioning addiction treatment services. There were 121,332 people who exited the drug and alcohol treatment system in 2017 to 2018, with 48% (58,718) having successfully completed their treatment, free from dependence.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 270772 question first answered 08/07/2019 16:08:50 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3932 label Biography information for Dr Dan Poulter